1. Search Result
Search Result
Results for "

1929

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Fluorescent Dye

3

Peptides

1

Inhibitory Antibodies

1

Isotope-Labeled Compounds

1

Antibodies

8

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1929
    Bivalirudin
    Maximum Cited Publications
    8 Publications Verification

    Thrombin Cardiovascular Disease
    Bivalirudin, a peptide anticoagulant, is a direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention .
    Bivalirudin
  • HY-B1470

    R-1929

    Dopamine Receptor Neurological Disease
    Azaperone (R-1929) acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic agent with antiemetic effects, which is used mainly as a tranquilizer in veterinary medicine.
    Azaperone
  • HY-15655
    GW1929
    Maximum Cited Publications
    8 Publications Verification

    PPAR Neurological Disease Metabolic Disease
    GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .
    GW1929
  • HY-P0150

    GCGR Neurological Disease
    Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
    Glucagon (19-29), human
  • HY-B1470S

    R-1929-d4

    Isotope-Labeled Compounds Dopamine Receptor Neurological Disease
    Azaperone-d4 is the deuterium labeled Azaperone. Azaperone (R-1929) acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic agent with antiemetic effects, which is used mainly as a tranquilizer in veterinary medicine.
    Azaperone-d4
  • HY-D1929

    Fluorescent Dye Others
    ATTO 594 NHS ester is a new fluorescent marker based on the Rhodamine structure. It has strong absorption, high fluorescence quantum yield, high thermal stability and photochemical stability, and is suitable for single molecule detection and high-resolution microscopy. ATTO 594 NHS ester is an NHS ester derivative of ATTO 594 that can be used to label proteins or antibodies.
    ATTO 594 NHS ester
  • HY-110022

    PPAR Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .
    GW1929 hydrochloride
  • HY-P99500

    RM-1929; Cetuximab-IRDye-700DX

    EGFR Cancer
    Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody). Cetuximab sarotalocan can be used for head and neck cancers research .
    Cetuximab sarotalocan
  • HY-R02742

    MicroRNA Cancer
    mmu-miR-1929-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    mmu-miR-1929-5p mimic
    mmu-miR-1929-5p mimic
  • HY-R02741

    MicroRNA Cancer
    mmu-miR-1929-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    mmu-miR-1929-3p mimic
    mmu-miR-1929-3p mimic
  • HY-RI02741

    MicroRNA Cancer
    mmu-miR-1929-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    mmu-miR-1929-3p inhibitor
    mmu-miR-1929-3p inhibitor
  • HY-RI02742

    MicroRNA Cancer
    mmu-miR-1929-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    mmu-miR-1929-5p inhibitor
    mmu-miR-1929-5p inhibitor
  • HY-R02741A

    MicroRNA Cancer
    mmu-miR-1929-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    mmu-miR-1929-3p agomir
    mmu-miR-1929-3p agomir
  • HY-R02742A

    MicroRNA Cancer
    mmu-miR-1929-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    mmu-miR-1929-5p agomir
    mmu-miR-1929-5p agomir
  • HY-RI02742A

    MicroRNA Cancer
    mmu-miR-1929-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    mmu-miR-1929-5p antagomir
    mmu-miR-1929-5p antagomir
  • HY-RI02741A

    MicroRNA Cancer
    mmu-miR-1929-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    mmu-miR-1929-3p antagomir
    mmu-miR-1929-3p antagomir
  • HY-B1470R

    Dopamine Receptor Neurological Disease
    Azaperone (Standard) is the analytical standard of Azaperone. This product is intended for research and analytical applications. Azaperone (R-1929) acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic agent with antiemetic effects, which is used mainly as a tranquilizer in veterinary medicine.
    Azaperone (Standard)
  • HY-P3617

    GCGR Metabolic Disease
    Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca 2+ pump in liver plasma membranes independently of adenylate cyclase activation .
    Glucagon (22-29)
  • HY-131190

    E3 Ligase Ligand-Linker Conjugates Cancer
    N-Boc-SBP-0636457-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates IAP ligand and a linker. N-Boc-SBP-0636457-OH can be used to design a PROTAC Bcl-xL degrader-1 (HY-131188) .
    N-Boc-SBP-0636457-O-C3-COOH
  • HY-131189

    Ligands for E3 Ligase Cancer
    N-Boc-SBP-0636457-OH, a ligand for E3 ubiquitin ligase, is used in the recruitment of IAP E3 ligases. N-Boc-SBP-0636457-OH can be connected to the ligand for Bcl-xL by a linker to form PROTAC Bcl-xL degrader-1 (HY-131188).
    N-Boc-SBP-0636457-OH
  • HY-131188

    PROTACs Bcl-2 Family Cancer
    PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL (Bcl-2 family member) ligand binding group, a linker and an IAP E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC50 values of 62 nM and 8.5 μM, respectively .
    PROTAC Bcl-xL degrader-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: